The aim of this review is to synthesize current evidence on lncRNA-mediated resistance mechanisms in HER2-positive breast cancer and to highlight translational opportunities for lncRNA-based biomarkers and therapeutic strategies. Here, ERBB2 is linked to breast carcinoma.